| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3195 | 2019 |
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 2988 | 2017 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2046 | 2017 |
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ... Nature 486 (7404), 532-536, 2012 | 2040 | 2012 |
| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1277 | 2019 |
| PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ... New England Journal of Medicine 386 (25), 2363-2376, 2022 | 876 | 2022 |
| Clinical sequencing defines the genomic landscape of metastatic colorectal cancer R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ... Cancer cell 33 (1), 125-136. e3, 2018 | 698 | 2018 |
| Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer RB Corcoran, T André, CE Atreya, JHM Schellens, T Yoshino, JC Bendell, ... Cancer discovery 8 (4), 428-443, 2018 | 551 | 2018 |
| Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ... Journal of clinical oncology 37 (4), 286-295, 2019 | 514 | 2019 |
| Adoption of total neoadjuvant therapy for locally advanced rectal cancer A Cercek, CSD Roxburgh, P Strombom, JJ Smith, LKF Temple, GM Nash, ... JAMA oncology 4 (6), e180071-e180071, 2018 | 510 | 2018 |
| Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS Z Yao, R Yaeger, VS Rodrik-Outmezguine, A Tao, NM Torres, MT Chang, ... Nature 548 (7666), 234-238, 2017 | 475 | 2017 |
| Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy JJ Smith, P Strombom, OS Chow, CS Roxburgh, P Lynn, A Eaton, ... JAMA oncology 5 (4), e185896-e185896, 2019 | 454 | 2019 |
| Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy J Garcia-Aguilar, S Patil, MJ Gollub, JK Kim, JB Yuval, HM Thompson, ... Journal of clinical oncology 40 (23), 2546-2556, 2022 | 435 | 2022 |
| A rectal cancer organoid platform to study individual responses to chemoradiation K Ganesh, C Wu, KP O’Rourke, BC Szeglin, Y Zheng, CEG Sauvé, ... Nature medicine 25 (10), 1607-1614, 2019 | 393 | 2019 |
| Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions AR Brannon, E Vakiani, BE Sylvester, SN Scott, G McDermott, RH Shah, ... Genome biology 15, 1-10, 2014 | 369 | 2014 |
| Targeting alterations in the RAF–MEK pathway R Yaeger, RB Corcoran Cancer discovery 9 (3), 329-341, 2019 | 363 | 2019 |
| Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and … J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, ... Journal of Clinical Oncology 39 (4), 273-284, 2021 | 353 | 2021 |
| Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence MH Nissan, CA Pratilas, AM Jones, R Ramirez, H Won, C Liu, S Tiwari, ... Cancer research 74 (8), 2340-2350, 2014 | 353 | 2014 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 312 | 2022 |
| EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ... Cancer discovery 10 (8), 1129-1139, 2020 | 306 | 2020 |
